• Cyclo (-RGDfC): αvβ3 Integrin Targeting

  2026-09-07

  Cyclo (-RGDfC), also written c(RGDfC), is a cyclic RGD peptide used to study αvβ3 integrin-mediated cell adhesion, migration, and tumor-targeting workflows. Its defined composition, DMSO solubility, and cold-storage specification support reproducible cancer research and angiogenesis research, but the reagent should not be interpreted as a standalone cytotoxic or clinical therapy.

• Elobixibat Hydrate: IBAT Mechanism and Research Use

  2026-09-07

  Elobixibat hydrate is a selective ileal bile acid transporter inhibitor that increases distal intestinal bile acid exposure and supports gastrointestinal motility. Product information describes applications in chronic idiopathic constipation, bowel preparation prior to colonoscopy, and metabolic research involving type 2 diabetes mellitus.

• Rosiglitazone in Adipose Browning Workflows

  2026-09-05

  Use Rosiglitazone as a controlled PPARγ benchmark for adipogenesis, insulin sensitivity modulation, and beige-fat thermogenesis assays. This workflow connects chemical activation with the SETD7–Adcy7–Sirt1–Creb1 axis, helping researchers distinguish adipocyte differentiation from thermogenic remodeling.

• Remdesivir (GS-5734) Beyond the Benchmark

  2026-09-05

  A translational framework for using Remdesivir (GS-5734) to connect polymerase biology, antiviral assay design, cross-virus evidence, and therapeutic prioritization.

• Tamoxifen Workflows for CreER and Cancer Models

  2026-09-04

  Tamoxifen combines temporal genetic control with clinically relevant cancer-biology applications, from CreER-mediated gene knockout to breast cancer research and kinase studies. This practical guide connects formulation, controls, mitochondrial iron assays, and troubleshooting to findings from a recent PINK1-deficient colon tumor study.

• Fludarabine: Reliable DNA Synthesis Inhibition

  2026-09-04

  Learn how Fludarabine (SKU A5424) can support reproducible viability, proliferation, and apoptosis workflows in leukemia and multiple myeloma research. This scenario-based guide covers mechanism, assay compatibility, formulation, optimization, data interpretation, and practical vendor selection.

• SIRT1/2 Inhibitor IV (cambinol) Guide

  2026-09-03

  A scenario-based laboratory guide to SIRT1/2 Inhibitor IV (cambinol), SKU B6063, for cell viability, proliferation, cytotoxicity, acetylation, and metabolic-pathway studies. It connects biochemical potency data with practical controls, dosing considerations, interpretation limits, and vendor-selection criteria.

• Tamoxifen Workflows for CreER and Cancer Research

  2026-09-02

  Tamoxifen is more than a breast cancer research reagent: it is a practical temporal switch for CreER-mediated gene knockout and a mechanistically rich perturbagen for cell and disease models. This guide connects formulation, conditional genetics, neuroimmune assays, and troubleshooting to improve experimental control and interpretation.

• Putting Mammalian Embryonic Cells into Dormancy

  2026-09-02

  This Nature Protocols study translates pharmacological mTOR inhibition into reproducible in vitro workflows for inducing and reversing a diapause-like state in mouse blastocysts, human blastoids, and pluripotent stem cells. Its practical value lies in replacing invasive in vivo procedures with scalable culture-based assays that combine dormancy induction, recovery, and developmental competence readouts.

• Mithramycin A for Transcription Assays

  2026-09-01

  Mithramycin A converts selective G-C-rich DNA recognition into a practical perturbation tool for transcription, c-myc regulation, and myeloid differentiation studies. This guide shows how to extend that established cancer biology use case into a carefully controlled, hypothesis-generating assay inspired by the miR-24-3p/Sp1/PI3K findings in doxorubicin-induced cardiac injury.

• Cefoperazone: Applied Research Workflows

  2026-09-01

  Cefoperazone sodium salt enables controlled antimicrobial screening, β-lactamase resistance studies, and PK-informed biliary tract infection research. This practical guide connects comparative evidence with preparation, assay design, troubleshooting, and defensible MIC/MBC interpretation.

• Lenalidomide (CC-5013) in Myeloma Workflows

  2026-08-31

  Build more informative multiple myeloma research workflows with Lenalidomide (CC-5013), combining viability, innate immune, and transcriptional readouts rather than relying on a single endpoint. This guide translates recent DOT1L–lenalidomide findings into practical dosing, combination, troubleshooting, and assay-design decisions.

• SAR405 for Reliable Vps34 Assays

  2026-08-31

  Learn how SAR405 (SKU A8883) can improve the interpretation of cell viability, autophagy, and vesicle-trafficking experiments through selective Vps34 inhibition. This scenario-based guide covers assay design, stock preparation, controls, data interpretation, and practical product selection.

• Nuclear mTORC1 and the TerminaTOR Inhibitor

  2026-08-30

  The reference study introduces TerminaTOR, a genetically encoded inhibitor that can be directed to defined subcellular compartments to separate lysosomal from nuclear mTORC1 functions. Its findings show that nuclear mTORC1 contributes to transcriptional regulation of CCAAT motif-containing genes, providing a spatially resolved framework for interpreting mTORC1 signaling.

• Perospirone: Receptor-to-Channel Assay Design

  2026-08-29

  Perospirone and SM-9018 free base offer a useful framework for connecting receptor pharmacology with vascular electrophysiology. This article presents an assay-first strategy for schizophrenia research, neuropsychiatric disorder models, and carefully bounded cardiovascular studies.

7910 records 1/528 page Next 12345 下5页 Last page